1. Pink Sheet

COVID-19 Vaccine Safety Now: Soft Rollout, Not Pause, After Reports Of Guillain-Barré Syndrome

 
• By Brenda Sandburg

Unlike its response to incidents of blood clots with J&J’s vaccine, the US FDA is not calling for a pause in its administration following reports of about 100 cases of Guillain-Barré syndrome. CDC advisory panel is to discuss the issue at an upcoming meeting.

J&J vaccine
CDC and FDA report rare cases of neurological disorder with J&J's COVID-19 vaccine • Source: Alamy

Johnson & Johnson’s COVID-19 vaccine has been associated with a small risk of Guillain-Barré syndrome, but unlike with its link to rare incidents of blood clots, the US Food and Drug Administration and Centers for Disease Control and Prevention are not requesting a pause in the administration of the shot.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet